Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

May 16, 2024

https://www.globenewswire.com/news-release/2024/05/16/2883249/36461/en/Voyager-Therapeutics-Announces-First-Participants-Dosed-in-Single-Ascending-Dose-Trial-of-VY-TAU01-for-the-Treatment-of-Alzheimer-s-Disease.html

LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer’s disease.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.